Isotretinoin is under clinical development by Trex Wind-Down and currently in Phase III for Harlequin Ichthyosis (Autosomal Recessive Congenital Ichthyosis 4B). According to GlobalData, Phase III drugs for Harlequin Ichthyosis (Autosomal Recessive Congenital Ichthyosis 4B) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Isotretinoin LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Isotretinoin overview
Isotretinoin (PAT-001) is under development for the treatment of moderate to severe congenital ichthyosis and X-linked recessive ichthyosis (XLRI). The drug candidate is formulated as a ointment and is administered through topical route. It acts by targeting retinoic acid receptor (RAR).
It was also under development for Darier’s disease, severe acne and sebaceous hyperplasia.
Trex Wind-Down overview
Trex Wind-Down is focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis, X-linked recessive, and other sclerotic skin. The company is headquartered in Warren, New Jersey, the US.
For a complete picture of Isotretinoin’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
